# Bilateral optic neuropathy following prolonged linezolid use: A case report

**Authors:** Hadiza Ometere Ibrahim, Aaesha Easa Alnuaimi, Amani Alzaabi, Mahfoud Elbashari, Mohammed Abouelnaga, Amna Almaazmi

PMC · DOI: 10.1016/j.idcr.2026.e02524 · IDCases · 2026-02-19

## TL;DR

A 65-year-old woman developed bilateral optic neuropathy after long-term linezolid use, highlighting the need for early detection and monitoring.

## Contribution

This case report identifies linezolid-associated optic neuropathy as a reversible but under-recognized complication of prolonged antibiotic therapy.

## Key findings

- Prolonged linezolid therapy led to bilateral optic neuropathy with visual decline and optic atrophy.
- Discontinuation of linezolid and cataract surgery resulted in partial visual recovery.
- Optical coherence tomography showed retinal nerve fiber layer thickening followed by optic atrophy.

## Abstract

This report describes a case of bilateral linezolid-associated optic neuropathy in a 65-year-old woman treated for Mycobacterium abscessus infection and highlights the importance of early recognition and intervention. The patient developed progressive, painless bilateral visual decline after more than six months of linezolid therapy. Ophthalmic examination revealed optic disc edema (left greater than right), impaired color vision, and prolonged visual evoked potential latencies. Neuroimaging excluded compressive or inflammatory etiologies, while optical coherence tomography demonstrated bilateral retinal nerve fiber layer thickening, with subsequent imaging showing optic atrophy in the left eye. Linezolid was discontinued, and a short empirical course of corticosteroids was administered. Visual function partially improved in the left eye following cataract extraction; however, residual optic atrophy and dyschromatopsia persisted. This case reinforces that linezolid-associated optic neuropathy is a potentially reversible yet under-recognized complication of prolonged therapy and emphasizes the need for routine ophthalmologic surveillance in patients receiving linezolid beyond recommended durations. A high index of suspicion is essential, as progressive bilateral visual loss may be misattributed to common ocular comorbidities such as cataracts, leading to delayed diagnosis and irreversible visual impairment.

•Bilateral optic neuropathy occurred after prolonged linezolid use.•OCT showed RNFL thickening and later optic atrophy.•Visual symptoms partially improved after drug cessation and cataract surgery.•Peripheral neuropathy supported mitochondrial toxicity.•Early ophthalmologic monitoring is essential in long-term linezolid therapy.

Bilateral optic neuropathy occurred after prolonged linezolid use.

OCT showed RNFL thickening and later optic atrophy.

Visual symptoms partially improved after drug cessation and cataract surgery.

Peripheral neuropathy supported mitochondrial toxicity.

Early ophthalmologic monitoring is essential in long-term linezolid therapy.

## Linked entities

- **Chemicals:** linezolid (PubChem CID 3929)

## Full-text entities

- **Diseases:** hyperemia (MESH:D006940), Peripheral neuropathy (MESH:D010523), autoimmune (MESH:D001327), non-insulin dependent type 2 diabetes mellitus (MESH:D003924), cataract (MESH:D002386), Bilateral optic neuropathy (MESH:C563492), NS3 (MESH:D009103), visual field defect (MESH:D005128), Mycobacterium abscessus cavitary lung infection (MESH:D009165), mitochondrial dysfunction (MESH:D028361), RAPD (MESH:D011681), visual decline (MESH:D014786), hypertension (MESH:D006973), optic atrophy (MESH:D009896), gram-positive infections (MESH:D016908), blurred optic disc (MESH:D009901), scotoma (MESH:D012607), inflammatory (MESH:D007249), disc edema (MESH:D010211), atrophy (MESH:D001284), edema (MESH:D004487), toxicity (MESH:D064420), exfoliation (MESH:D017889), color (MESH:D003117), lactic acidosis (MESH:D000140), infections (MESH:D007239)
- **Chemicals:** steroid (MESH:D013256), ATP (MESH:D000255), oxazolidinone (MESH:D023303), tigecycline (MESH:D000078304), Linezolid (MESH:D000069349), amikacin (MESH:D000583)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12955222/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12955222/full.md

## References

9 references — full list in the complete paper: https://tomesphere.com/paper/PMC12955222/full.md

---
Source: https://tomesphere.com/paper/PMC12955222